

537, 264

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/052273 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number:
PCT/BR2003/000192
- (22) International Filing Date: 9 December 2003 (09.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PI0205449-3 9 December 2002 (09.12.2002) BR
- (71) Applicant (for all designated States except US): **BIOLAB SANUS FARMACÊUTICA LTDA.** [BR/BR]; 5386 dos Bandeirantes Av., Planalto Paulista, 04071-900 São Paulo (BR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **CAMARGO, Antônio** [BR/BR]; 125 Mirajuba St., Alto de Pinheiros, 05467-010 São Paulo (BR). **SANTOS, Robson** [BR/BR]; 48 Deputado Wilson Tanure St., Saint Amélia, 31560-240 Belo Horizonte (BR). **MILLÁN, Rubén** [BR/BR]; 64 João Antonio Cardoso St., RM 301, 31310-390 Belo Horizonte (BR). **IANZER, Danielle** [BR/BR]; 136 Francisco Estácio Fortes St., 01233-060 São Paulo (BR).
- (74) Agent: **LLC INFO CONNECTION LTDA.**; 5555 Dom Hélder Câmara Av., RM 312, Pílares, 20771-001 Rio de Janeiro (BR).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITIONS PREPARATION OF PEPTIDES, SECRETED BY THE SNAKE VENOM GLANDS, PARTICULARY OF BOTHROPS JARARACA, VASOPEPTIDASES INHIBITORS, EVASINS, THEIR ANALOGUES, DERIVATIVES AND PRODUCTS ASSOCIATED, THEREOF. FOR DEVELOPMENT OF APLICATIONS AND USE IN CHRONIC-DEGENERATIVE DISEASES

(57) Abstract: The present invention is characterized by the process of preparation of pharmaceutical compositions for the development of applications of the Evasins and their structural and/or conformational analogues in chronic-degenerative diseases. It s further characterized by the process of preparation of pharmaceutical compositions and related products of the Evasins peptides and their structural and/or conformational analogues in using the cyclodextrins, its derivatives, liposomes and biodegradable polymers and/or mixture of these systems.The present invention is also characterized by the identification of new biochemical and physio-pharmacological mechanisms not related to the effects on the bradykinin metabolism and angiotensin II formation, which contributes for the mechanism of action of these peptides in chronic-degenerative disorders. In the state-of-art no application was found which uses the Evasins and their analogues included in the cyclodextrins, liposomes, the biodegradable polimers and their derivatives, for the study and treatment of hypertension or other cardiovascular or chronic-degenerative diseases. This characterizes the present invention as a new and more efficient alternative for the study and treatment of these pathologies and their complications.It is further characterized by the increased efficacy of these peptides and their analogues included in cyclodextrins, when administered to rats. This characterizes an increased biodisponibility of these peptides and their analogues using the compositions of the present invention.

WO 2004/052273 A2